Pharvaris (NASDAQ:PHVS) Trading 5.1% Higher

Shares of Pharvaris (NASDAQ:PHVS) traded up 5.1% during trading on Monday . The company traded as high as $17.14 and last traded at $17.00. 52,495 shares changed hands during trading, a decline of 37% from the average session volume of 82,686 shares. The stock had previously closed at $16.18.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PHVS. Morgan Stanley reiterated an “overweight” rating and issued a $34.00 target price on shares of Pharvaris in a report on Monday, April 22nd. JMP Securities boosted their target price on Pharvaris from $49.00 to $50.00 and gave the stock a “market outperform” rating in a report on Thursday, April 11th. Wedbush cut their price target on shares of Pharvaris from $35.00 to $31.00 and set an “outperform” rating on the stock in a report on Thursday, May 9th. Finally, Oppenheimer lifted their price target on shares of Pharvaris from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Wednesday, July 3rd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.80.

Pharvaris Price Performance

The company has a market cap of $556.88 million, a PE ratio of -6.53 and a beta of -3.10. The company has a 50-day moving average price of $17.76 and a two-hundred day moving average price of $21.95.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.56) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.56). On average, equities research analysts anticipate that Pharvaris will post -2.39 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Blackstone Inc. acquired a new position in Pharvaris in the 4th quarter worth $2,805,000. Vivo Capital LLC acquired a new position in shares of Pharvaris in the fourth quarter worth about $7,994,000. Commodore Capital LP purchased a new position in Pharvaris in the fourth quarter valued at about $22,440,000. Finally, venBio Partners LLC boosted its holdings in Pharvaris by 15.4% in the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock valued at $137,992,000 after purchasing an additional 654,832 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.